

BASAL CELL EPITHELIOMA INDUCED BY IBRUTINIB: TWO CASE REPORTS

Gálvez Madroñero M, Barcia Martín MI, Sanmartín Fenollera P, Villalón Blanco L, Peñalver Parraga FJ, Pérez Encinas M.
Hospital Universitario Fundación Alcorcón. Madrid (Spain)

BACKGROUND

Ibrutinib is a tyrosine kinase inhibitor indicated for treatment of chronic lymphocytic leukaemia. Its considered a safe drug; however, one of the adverse reactions described is non-melanoma skin cancer

MATERIAL Y METHODS

Descriptive and retrospective clinical cases. Data were obtained by the electronic medical records. A literature search was conducted on the adverse effects of ibrutinib. The causality of the adverse reaction was established using the Karch-Lasagna Algorithm (KLA)

PURPOSE

To describe two cases of basal cell epithelioma (BEC) in patients with chronic lymphocytic leukaemia treated with ibrutinib and to establish the causality of the adverse reaction

RESULTS

CASE 1

WOMAN

Chronic lymphocytic leukaemia

70 years old

4th line treatment

No skin history

February
2016

February
2017

**BASAL CELL
EPITHELIOMA**
By Dermatology
Service

✓ START
TREATMENT

✗ CRUSTAL LESION
ON THE NOSE

IBRUTINIB 420 mg c/24h

CASE 2

MAN

Chronic lymphocytic leukaemia

69 years old

3th line treatment

Basal cell epithelioma previous in chekk, temporal region, earbole and shoulder

October
2016

January
2017

**BASAL CELL
EPITHELIOMA**
By Dermatology
Service

✓ START
TREATMENT

✗ NOSE AND CHEEK
INJURY

In both patients:

- Mohs surgery was indicated
- Complete wound healding
- Given a good response to the treatment
- Hematology Service maintained Ibrutinib under close follow-up
- Possible causal relationship between ibrutinib and the occurrence of BCE by KLA
- Conventional chemotherapy previosuly
- These possible adverse reactions were reported to the National Pharmacovigilance System.

CONCLUSION

The new oral antineoplastic drugs have demonstrated efficacy and safety in Clinical Trials. However, possible adverse effects can be observed. It is important the health professionals know the drug adverse effects, how to handle them and to carry out a close follow-up of the patient. In the event of any suspicion, it is important to notify the Official Organizations.

ACKNOWLEDGEMENTS

To everyone in the Departament of Clinical Hematology.

